Abbvie Inc ABBV:NYSE

Last Price$151.01NYSE Previous Close - Last Trade as of 7:00PM ET 5/20/22
NYSE 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$151.01 (4)
Ask (Size)$151.52 (1)
Day Low / HighN/A - N/A
Volume6.7 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/20/2022


Abbvie Inc ( NYSE )

Price: $151.01
Change: -0.71 (0.47%)
Volume: 6.7 M
7:00PM ET 5/20/2022

Eli Lilly and Co ( NYSE )

Price: $298.85
Change: +12.58 (4.39%)
Volume: 3.1 M
7:00PM ET 5/20/2022

Pfizer Inc ( NYSE )

Price: $52.47
Change: +1.82 (3.59%)
Volume: 31.3 M
7:00PM ET 5/20/2022

Merck & Co Inc ( NYSE )

Price: $93.55
Change: +1.46 (1.59%)
Volume: 11.8 M
7:00PM ET 5/20/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $76.19
Change: +0.23 (0.30%)
Volume: 17.3 M
7:00PM ET 5/20/2022

Read more news Recent News

--Berenberg Bank Adjusts AbbVie's Price Target to $135 From $115, Maintains Hold Rating
9:16AM ET 5/20/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AbbVie Says It Has Filed New Drug Application With FDA for Advanced Parkinson's Disease Treatment
9:10AM ET 5/20/2022 MT Newswires

AbbVie (ABBV) said Friday it has filed a new drug application with the US Food and Drug Administration for its ABBV-951 treatment of motor fluctuations in...

Insider Sell: Abbvie
5:16PM ET 5/18/2022 MT Newswires

Michael Severino, Vice Chairman, on May 16, 2022, sold 200,000 shares in Abbvie (ABBV) for $30,849,488. Following the Form 4 filing with the SEC, Severino...

Insider Sell: Abbvie
5:16PM ET 5/18/2022 MT Newswires

Henry O Gosebruch, Executive Vice President, Chief Strategy Officer, on May 16, 2022, sold 83,960 shares in Abbvie (ABBV) for $13,013,800. Following the...

View all Commentary and Analysis

Options Income Series: How To Earn High Income In This Tough Market - May 2022
9:30AM ET 5/21/2022 Seeking Alpha

Baron Health Care Fund Q1 2022 Shareholder Letter
12:40AM ET 5/21/2022 Seeking Alpha

3 Reasons To Forget VYM And Build Your Own Portfolio Instead
5:46PM ET 5/20/2022 Seeking Alpha

Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
8:00AM ET 5/20/2022 Zacks

Recently, users have been paying close attention to AbbVie (ABBV). This makes it...

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Number of Employees30,000
Recent SEC Filing05/20/20224/A
Chairman & Chief Executive OfficerRichard A. Gonzalez
President & Vice Chairman-Management BoardMichael E. Severino
CFO, Vice Chairman-Finance & Commercial OperationsRobert A. Michael
Chief Scientific Officer, Senior VP-R&DThomas J. Hudson

Company Highlights

Price Open$152.33
Previous Close$151.72
52 Week Range$105.56 - 175.91
Market Capitalization$266.9 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 3.73%
Dividend Ex-Date04/13/2022
Dividend Pay-Date05/16/2022
Dividend Yield 5 Year Average4.08%
Next Earnings Announcement07/29/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings22.02
Earnings per Share$8.17
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin21.86%
Return on Equity85.78%

Analyst Ratings as of 05/04/2022

Consensus RecommendationConsensus Icon
Powered by Factset